Flurpiridaz (18F)
A radiopharmaceutical used in PET imaging of the heart
Flurpiridaz (18F) is a radiopharmaceutical used in positron emission tomography (PET) imaging, specifically for the assessment of myocardial perfusion. It is a fluorine-18 labeled compound that binds to mitochondrial complex I, allowing for detailed imaging of the heart's blood flow.
Chemical Properties
Flurpiridaz (18F) is a fluorine-18 labeled pyridazinone derivative. The presence of the radioactive isotope fluorine-18 allows it to be used in PET imaging due to its positron-emitting properties. The chemical structure of Flurpiridaz (18F) facilitates its binding to mitochondrial complex I, which is abundant in cardiac tissue.
Mechanism of Action
Flurpiridaz (18F) works by targeting mitochondrial complex I in the heart muscle cells. This complex is a crucial part of the electron transport chain, which is involved in cellular respiration. By binding to this complex, Flurpiridaz (18F) allows for the visualization of myocardial perfusion, providing insights into the blood flow and function of the heart muscle.
Clinical Applications
Flurpiridaz (18F) is primarily used in the evaluation of myocardial perfusion. It is particularly useful in patients with suspected or known coronary artery disease (CAD). The high resolution and quantitative capabilities of PET imaging with Flurpiridaz (18F) make it a valuable tool in assessing the severity and extent of CAD, as well as in evaluating the effectiveness of therapeutic interventions.
Advantages over Other Imaging Agents
Compared to traditional SPECT imaging agents, Flurpiridaz (18F) offers several advantages:
- Higher Resolution: PET imaging provides superior spatial resolution compared to SPECT, allowing for more detailed images of the heart.
- Quantitative Analysis: PET allows for quantitative assessment of myocardial blood flow, which can be critical in evaluating the severity of CAD.
- Shorter Half-life: The half-life of fluorine-18 is approximately 110 minutes, which is shorter than some other isotopes, reducing radiation exposure to the patient.
Development and Approval
Flurpiridaz (18F) is currently under investigation in clinical trials to further establish its safety and efficacy. It has shown promise in early studies, demonstrating superior image quality and diagnostic accuracy compared to existing imaging agents.
Related pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
